title: Efficacy of motesanib diphosphate in non-small-cell lung cancer.
abstract: BACKGROUND
  Angiogenesis plays a crucial role in the proliferation and in the metastatic spread of tumour cells. Several agents with anti-angiogenic activity have been tested in advanced non-small-cell lung cancer (NSCLC) patients. Motesanib (AMG 706) is a promising anti-angiogenic multi-targeted tyrosine kinase inhibitor (TKI), which has been investigated as a monotherapy or in combination with chemotherapy, in several types of cancer.
  
  
  METHODS
  We have reviewed the literature, and we have presented the results of clinical trials that have investigated the administration of motesanib in advanced NSCLC patients.
  
  
  CONCLUSIONS
  Encouraging results have been described with the administration of motesanib as first-line treatment in combination with carboplatin and paclitaxel in Asian patients with non-squamous advanced NSCLC. Further studies are needed in order to identify the predictive biomarkers of response and to select patients who may benefit from this anti-angiogenic treatment.
authors.affiliation: IRCCS AOU San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, UOS Tumori Polmonari , Largo Rosanna Benzi No 10, 16132 Genova , Italy +39 0105600665 ; +39 0105600795 ; ery80x@yahoo.it.
authors.forename: Erika
authors.initials: E
authors.lastname: Rijavec
authors.forename: Carlo
authors.initials: C
authors.lastname: Genova
authors.forename: Giulia
authors.initials: G
authors.lastname: Barletta
authors.forename: Federica
authors.initials: F
authors.lastname: Biello
authors.forename: Maria Giovanna
authors.initials: MG
authors.lastname: Dal Bello
authors.forename: Simona
authors.initials: S
authors.lastname: Coco
authors.forename: Anna
authors.initials: A
authors.lastname: Truini
authors.forename: Irene
authors.initials: I
authors.lastname: Vanni
authors.forename: Angela
authors.initials: A
authors.lastname: Alama
authors.forename: Francesco
authors.initials: F
authors.lastname: Boccardo
authors.forename: Francesco
authors.initials: F
authors.lastname: Grossi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009841:Oligonucleotides; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D009841:Oligonucleotides; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D016190:Carboplatin; D011505:Protein-Tyrosine Kinases; C519562:imetelstat; D017239:Paclitaxel
keywords: angiogenesis; motesanib; multi-targeted tyrosine kinase inhibitors; non-small-cell lung cancer